Sglt 2 denied as experimental or investigational by Aetna?

Aetna's specific coverage criteria for sglt2 are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna May Deny an SGLT2 Inhibitor as "Experimental"

Aetna's "experimental or investigational" denial for an SGLT2 inhibitor typically arises when the specific use being requested — a particular indication, patient population, or combination — is not yet recognized in Aetna's published clinical policy, even if the drug itself is FDA-approved for other indications. Aetna's clinical policies often lag behind evolving FDA approvals and major cardiology, nephrology, or diabetes guideline updates.

This is an appealable denial. FDA approval for a specific indication is the primary legal standard; payer "experimental" classifications that contradict an existing FDA approval are routinely overturned on external review.

## Federal Appeal Framework

• Internal appeal — file promptly. Aetna must decide standard pre-service appeals within 30 days under ERISA. Urgent appeals require a 72-hour decision.
• External review (ACA §2719 / ERISA §503) — "experimental" denials are explicitly subject to independent external review. This is a meaningful protection: an independent organization with relevant clinical expertise reviews whether the treatment is truly experimental. The external-review window is generally within approximately four months of the original denial. Expedited review is available for urgent situations.

## Documentation to Gather

• Current FDA-approved prescribing label — identify the exact indication for which the drug is approved and confirm the prescribed use falls within it. If the use is within an approved indication, the "experimental" label is factually incorrect.
• Aetna's current clinical policy on SGLT2 inhibitors — identify precisely which use Aetna has classified as experimental and what evidence standard it applies.
• Current professional guideline organization position — obtain a copy of the relevant guideline (from organizations such as the applicable ACC/AHA, ADA, KDIGO, or Heart Failure Society body) that addresses this indication. Note whether the use is recommended and at what evidence tier, without citing specific numbers.
• Prescriber letter of medical necessity — the prescriber should state that the prescribed use is within an FDA-approved indication and/or is supported by the applicable professional guideline, identify the guideline organization by name, and explain the clinical rationale for this specific patient.
• Specialist consultation notes — if applicable, a cardiologist, nephrologist, or endocrinologist note supporting the prescribed use strengthens the appeal significantly.

## Criteria-Mapping Structure

| Aetna "Experimental" Criterion | Your Evidence | |---|---| | Is the drug FDA-approved? | [Yes — label citation + approval date] | | Is this specific use within an approved indication? | [Label indication language + prescriber's diagnosis] | | Is the use supported by a major guideline organization? | [Guideline org name + recommendation statement] | | Any Aetna-specific exception criterion | [Corresponding chart fact] |

## Key Argument

A treatment cannot be "experimental" when it carries an FDA approval for the indication being treated. Aetna's clinical policy cannot override FDA approval status. Demand that Aetna identify the specific basis for the experimental classification and respond point by point. External reviewers consistently side with treating clinicians when a use is both FDA-approved and guideline-supported.